Imunon (IMNN) said Friday it received positive data showing improvement in overall and progression-free survival from a phase 2 study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.
The 112-patient study showed those treated with IMNN-001 plus chemotherapy had a median overall survival length of 46 months compared to 33 months for those treated with standard of care, the company said.
Imunon said it recently initiated the first two sites for a phase 3 study of the drug in newly diagnosed advanced ovarian cancer.
Shares of the company soared more than 145% in recent premarket activity.
Price: 1.00, Change: +0.58, Percent Change: +145.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.